Breaks Categories: News

ThursdayOct 07, 2021 12:31 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Collaboration with University of Wisconsin Researchers to Evaluate TRP-8803

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, this morning announced a collaboration to support clinical pharmacology studies for Tryp’s proprietary drug product TRP-8803. Dr. Paul Hutson, Professor of the Pharmacy Practice Division at the University of Wisconsin-Madison School of Pharmacy and Dr. Christopher Nicholas, Assistant Professor at the University of Wisconsin School of Medicine, will serve as investigators on the clinical pharmacology studies to assess the pharmacokinetics and safety of TRP-8803 in healthy, volunteer patients. The completion of the studies is anticipated to deliver additional regulatory support…

Continue Reading

WednesdayOct 06, 2021 10:53 am

PsychedelicNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Delic Labs Moves Forward with Strategic Steps toward Commercialization

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced that Delic Labs, which is part of the Delic Corp. family, has applied for a Health Canada 56 Research Exemption. Approval of the application allows Delic Labs scientists to perform research and tests on compounds in addition to psychedelic mushrooms, which it currently holds a 56 research exemption to study. The new application would allow the lab to study substances such as MDMA and LSD. The lab has also submitted an application for a dealer’s license. These steps are part of a strategic plan leading toward…

Continue Reading

TuesdayOct 05, 2021 10:01 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Names Keynote Speaker for Upcoming Premiere Psychedelic and Wellness Event

Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced the keynote speaker for its upcoming Meet Delic event, a revolutionary, two-day immersive edutainment experience designed to bring together the world's leading psychedelic and wellness thought and business leaders. Dr. Molly Maloof, MD, will speak at the premiere event, which will take place on Nov. 6, 2021. Maloof has an impressive background of working with investors, entrepreneurs, and executives to optimize their health. She has also consulted with an estimated 45 companies that operate in the digital health, consumer health and biotechnology industries. Cofounder of the…

Continue Reading

FridayOct 01, 2021 10:11 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Appoints New Executives, Promotes Team Members

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has named two new executive team members. The company has named Dr. Amir Inamdar as the chief medical officer for its European operations and Dr. Geoff Varty as the  new head of research & development. In addition, the company has made some internal promotions, naming Lori Challenger as chief compliance, ethics & administrative officer and Robert Mino as general counsel. A trained psychiatrist and pharmaceutical physician with more than two decades of clinical and drug-development experience, Inamdar has deep expertise in progressing numerous drugs from preclinical development…

Continue Reading

ThursdaySep 30, 2021 1:12 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Enters First-of-Its-Kind Partnership with Paradigm Healthcare

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced a first-of-its-kind partnership with Paradigm Healthcare, an independent clinical laboratory located in St. Simons, Georgia, with a focus on high complexity, clinical toxicology, to bring state-of-the-art testing to Ketamine Infusion Centers LLC (“KIC”). Under the partnership, KIC will have access to Paradigm’s Benchmark UDT(TM) toxicology solution that utilizes LC/MS/MS test methods to identify and accurately measure drug compounds in the body, ensuring the highest quality toxicology results and clinically relevant test data to support medical decision making. “Paradigm’s Benchmark testing platform brings state-of-the-art drug testing…

Continue Reading

TuesdaySep 28, 2021 10:11 am

PsychedelicNewsBreaks – Delic Holdings Inc.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Meet Delic to Showcase Lamar Odom’s Path to Healing with Psychedelics

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, today announced that two-time NBA champion Lamar Odom will headline Meet Delic on Nov. 7, 2021. Odom’s professional basketball career spanned 15 years, including seven as a forward with the Los Angeles Lakers that earned him 2009 and 2010 NBA championships. Odom joined LeBron James, Allen Iverson, Tim Duncan and Dwayne Wade as members of the gold-winning U.S. men’s basketball team at the 2004 Athens Olympics. In 2015, Odom was hospitalized in Las Vegas after a near-death overdose resulting in multiple seizures, strokes and a coma. An upcoming documentary…

Continue Reading

WednesdaySep 22, 2021 2:08 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA"). The clinical trial is designed to evaluate the efficacy of TRYP’s clinical candidate, TRP-8802, for the treatment of patients with eating disorders. TRYP is working with Jennifer Miller, MD, from the University of Florida, to conduct the trial as well as evaluate its oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. The IND application outlines specifics in regard to the safety of…

Continue Reading

MondaySep 20, 2021 1:11 pm

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) Announces Planned Acquisition of Ketamine Wellness Centers Inc.

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has announced plans to merge with Ketamine Wellness Centers Arizona LLC (“KWC”), which would create the largest psychedelic wellness chain in the country. The binding merger agreement would create 12 open locations — 10 KWC locations and two Delic locations — with plans in place to open 15 additional clinics in the next 18 months. KWC’s ketamine infusion treatment clinics are located in Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas and Washington; Delic’s clinics are in California and Arizona. “This is a game changer for the future of health and psychedelic wellness in America,” said Delic cofounder and…

Continue Reading

ThursdaySep 16, 2021 10:27 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Participation in Oppenheimer Fall Healthcare Summit

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, will be a featured presenter at the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. The three-day event, scheduled for Sept. 20–23, 2021, will be a virtual event. Tryp CEO and chair Greg McKee will be part of the agenda with a company presentation slated to begin on Sept. 21 at 3:35 p.m EDT. The presentation will include a company overview as well as a discussion about Tryp’s pipeline as well as its for psilocybin-for-neuropsychiatric disorders, or PFN(TM) (“PFN”)…

Continue Reading

FridaySep 10, 2021 11:50 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Keynote Speaker Chris Ryan, Ph.D., for World’s Premiere Psychedelic and Wellness Event

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), the leading psychedelic wellness platform, has announced that Chris Ryan, Ph.D., will serve as one of the headline speakers on Nov. 7, 2021, at Meet Delic, the largest and most comprehensive event to learn about the intersection of psychedelics, wellness and business. In his keynote, “Psychedelics and the Search for Truth,” Ryan will explore the emerging potential for psychedelics to reshape the modern world. Ryan is the New York Times best-selling co-author of “Sex at Dawn: How We Mate, Why We Stray, and What it Means for Modern Relationships.” He also hosts…

Continue Reading